STANISLAW R BURZYNSKI, M.D., PH.D.
Ambulatory Health at Old Katy Rd, Houston, TX

4558057, Dec 10, 1985

Aug 20, 1984

6/642499

Stanislaw R. Burzynski - Houston TX

A61K 3700, C07D21140

514328

Highly purified fractions from human urine exhibiting antineoplastic activity and processes for their preparation are described. The fractions comprise biologically active, small sized, low molecular weight peptides which exert cytostatic and cytotoxic activity toward neoplastic cell cultures and human neoplastic diseases. The fractions have been termed antineoplaston fractions. An antineoplastic active peptide common to each of the various antineoplaston fractions has been isolated and identified as 3-[N-phenylacetylaminopiperidine]-2, 6-dion. A synthetic mechanism for the preparation of 3-[N-phenylacetylaminopiperdine]-2, 6-dion is also disclosed, involving a combination reaction between L-glutamine and phenylacetyl chloride. Also disclosed are the hydrolysis degradation products of 3-[N-phenylacetylaminopiperidine]-2, 6-dion which also exhibit antineoplastic activity when administered according to the general teachings presented in this disclosure.

5116622, May 26, 1992

Sep 12, 1990

7/581022

Stanislaw R. Burzynski - Houston TX

A61K 3522

424545

The present invention provides methods for treating Parkinson's disease by administering to an afflicted host pharmaceutical compositions containing a therapeutically effective amount of urine peptide fractions containing 3-[N-phenylacetylaminopiperidine]-2,6-dion. The therapeutically effective urine peptide fractions of this invention, termed Antineoplastons A2 and A5, are obtained by two separate processes: Antineoplaston A2 is prepared by providing a volume of urine; separating from the urine particulate matter and matter having a molecular weight greater than about 5000; acidifying the urine; separating from the acidified urine any precipitated matter; introducing the acidified urine to a first chromatography column containing a polymeric resin adsorbent; eluting the column to recover an eluate; adjusting the pH of the eluate to between about 2 and 8; introducing the adjusted eluate to a second chromatography column; and recovering the peptide fraction containing the compound 3-[N-phenylacetylaminopiperidine[-2,6-dion. Antineoplaston A5 is prepared by providing a volume of urine; separating from the urine particulate matter and matter having a molecular weight greater than about 5000; acidifying the urine; separating from the acidified urine any precipitated matter; introducing the acidified urine to a chromatography column; eluting the column with a lower alkyl alcohol having from 1 to 8 carbon atoms; and recovering the peptide fraction containing the compound 3-[N-phenylacetylaminopiperidine]-2,6-dion.

2003010, Jun 5, 2003

Nov 27, 2001

09/995010

Stanislaw Burzynski - Houston TX, US

A61K031/525, A61K031/198, A61K031/185

514/251000, 514/565000, 514/561000, 514/553000

Pharmaceutical compositions effective in alleviating or reducing the effects of fatigue and weakness associated with cancer and cytotoxic cancer chemotherapy are disclosed. The pharmaceutical compositions of the present invention comprise riboflavin, effectors of the urea cycle in free form or pharmacologically acceptable salts thereof, and amino acids selected from the groups of essential and non-essential amino acids, in free form or pharmaceutically acceptable salts thereof, suitably combined with appropriate carriers, diluents, or excipients. Also disclosed are methods of alleviating or reducing the effects of fatigue and weakness associated with cancer and cytotoxic cancer chemotherapy by administration of pharmaceutical compositions of the present invention.

4559325, Dec 17, 1985

Aug 20, 1984

6/642873

Stanislaw R. Burzynski - Houston TX

A61K 3700, C07G 700

514 21

Highly purified fractions from human urine exhibiting antineoplastic activity and processes for their preparation are described. The fractions comprise biologically active, small sized, low molecular weight peptides which exert cytostatic and cytotoxic activity toward neoplastic cell cultures and human neoplastic diseases. The fractions have been termed antineoplaston fractions. An antineoplastic active peptide common to each of the various antineoplaston fractions has been isolated and identified as 3-[N-phenylacetylaminopiperidine]-2, 6-dion. A synthetic mechanism for the preparation of 3-[N-phenylacetylaminopiperdine]-2,6-dion is also disclosed, involving a combination reaction between L-glutamine and phenylacetyl chloride. Also disclosed are the hydrolysis degradation products of 3-[N-phenylacetylaminopiperidine]-2, 6-dion which also exhibit antineoplastic activity when administered according to the general teachings presented in this disclosure.

7427619, Sep 23, 2008

Apr 18, 2005

11/108277

Stanislaw R. Burzynski - Houston TX, US

A61K 31/525, A61K 31/415, A61K 31/40, A61K 31/205, A61K 31/19, A61K 31/195

514251, 514400, 514419, 514423, 514556, 514557, 514561, 514562

Pharmaceutical compositions effective in alleviating or reducing the effects of fatigue and weakness associated with cancer and cancer chemotherapy are disclosed. The pharmaceutical compositions of the present invention comprise riboflavin, effectors of the urea cycle in free form or pharmacologically acceptable salts thereof, and amino acids selected from the groups of essential and non-essential amino acids, in free form or pharmaceutically acceptable salts thereof, suitably combined with appropriate carriers, diluents, or excipients. Also disclosed are methods of alleviating or reducing the effects of fatigue and weakness associated with cancer and cancer chemotherapy by administration of pharmaceutical compositions of the present invention.

2006020, Sep 14, 2006

Mar 1, 2006

11/365289

Stanislaw Burzynski - Houston TX, US

A61K 31/198, A61K 31/192

514563000, 514570000

Provided are methods of treating von Hippel-Lindau disease (VHL). Specifically embodiments of the invention provide methods for the treatment of a patient afflicted with VHL using phenylacetyl-derivatives. Preferred embodiments of the invention provide for the use of phenylacetic acid (or its sodium salt), phenylacetylglutamine (or its sodium salt) and/or phenylacetylisoglutamine (or its sodium salt) to treat VHL. Other embodiments of the invention provide for the use of phenylacetyl-derivatives for the manufacture of a medicament for the treatment of VHL.

5244922, Sep 14, 1993

May 27, 1992

7/888976

Stanislaw R. Burzynski - Houston TX

A61K 31195

514561

The present invention provides methods for treating viral diseases in humans by administering to an afflicted host pharmaceutical compositions containing a therapeutically effective amount of a combination of ##STR1## in a weight ratio ranging from about 1:1 to about 1:10 (A:B); wherein R is OH, NH. sub. 2, OW, or H; X is H, F, Cl, Br, I, OH, OW, NO. sub. 2, or NH. sub. 2 ; Y is H, F, Cl, Br, or I; W is ##STR2## or a C. sub. 1 to C. sub. 12 aliphatic group; Z is an aliphatic or aromatic group of C. sub. 1 to C. sub. 12 ; X and Y can both vary within the compound; or pharmaceutically acceptable salts thereof. Particularly disclosed herein is a composition comprising a 1 to 4 ratio of the sodium salts of phenylacetylglutamine and phenylacetic acid, formulated in both oral and parenteral forms clinically useful in the treatment of herpes virus, HIV, human papilloma virus, rhinovirus, coronavirus, orthomyxovirus and paramyxovirus.

5254587, Oct 19, 1993

Nov 8, 1991

7/790584

Stanislaw R. Burzynski - Houston TX

A61K 31195

514563

The present invention provides methods for treating AIDS-related diseases by administering to an afflicted host pharmaceutical compositions containing a therapeutically effective amount of substituted piperidinedione of the formula ##STR1## or mixtures thereof, wherein R is OH, NH. sub. 2, OW, or H; X is H, F, Cl, Br, I, OH, OW, NO. sub. 2, or NH. sub. 2 ; Y is H, F, Cl, Br, or I; W is ##STR2## or a C. sub. 1 to C. sub. 12 aliphatic group; Z is an aliphatic or aromatic group of C. sub. 1 to C. sub. 12 ; X and Y can both vary within the compound; and pharmaceutically acceptable salts thereof. The pharmaceutical compositions further may include R,X,Y substituted phenylacetic acid.

4918193, Apr 17, 1990

Jan 11, 1989

7/295372

Stanislaw R. Burzynski - Houston TX

C07D21140

546220

Disclosed is a process for synthesizing 3-[N-phenylacetylaminopiperidine]-2,6-dion, which process comprises the steps of providing a quantity of L-glutamine, providing a quantity of phenylacetyl halide, mixing together the L-glutamine and phenylacetyl halide in a weakly alkaline aqueous solution to provide an aqueous reaction mixture, adjusting the reaction mixture to a pH ranging from about 2 to about 3, and recovering from the reaction mixture the product 3-[N-phenylacetylamino-piperidine]-2,6-dion, and when desired preparing the pharmaceutically acceptable salts thereof.

7087219, Aug 8, 2006

May 28, 2003

10/446536

Stanislaw R. Burzynski - Houston TX, US
Wojciech Gruszecki - Berlin, DE

A61K 8/00, A61K 8/21, A61K 8/40, A61K 8/41

424 49, 424 52, 424 54, 433215, 433216, 4332281

A novel dentifrice composition is provided for prevention or treatment of carcinoma of the oral cavity, caries and periodontal diseases of the oral cavity. The dentifrice composition contains a partially water-soluble calcium salt, a medicinal composition useful in the treatment of human neoplastic disease, and a hydrophilic or hydrophobic liquid vehicle. A preferred dentifrice composition is a toothpaste comprising gypsum, 3-N-phenylacetylamino-2,6-dione, gypsum, paraffin oil and a mixture of natural flavoring oils. The components of the dentifrice composition act advantageously to allow the composition to remove plaque, tartar, and oral disease-causing bacteria.